Search Results

Press Releases

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

April 11, 2025

·

18 min read

Press Releases

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

April 8, 2025

·

4 min read

Deals

GSK Pays $430M Upfront for CureVac’s COVID-19, Flu mRNA Vaccines

GSK on Wednesday restructured its contract with CureVac to gain access to the biotech’s influenza and COVID-19 programs for $430 million upfront and up to $1.13 billion in future payments.

July 3, 2024

·

2 min read

·

Tristan Manalac

Press Releases

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators

February 19, 2025

·

6 min read

Press Releases

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

April 7, 2025

·

8 min read

Business

CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update

CureVac N.V. (Nasdaq:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the first quarter of 2024 and provided a business update.

May 23, 2024

·

12 min read

Business

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

CureVac N.V. today announced that Thaminda Ramanayake has been appointed to the role of Chief Business Officer, effective June 1, 2024.

April 24, 2024

·

7 min read

Bernd Weissbrod/picture alliance via Getty Images

Policy

German Court Nullifies CureVac’s Patent Case Against BioNTech

A court in Germany on Tuesday nullified one of CureVac’s intellectual property rights in a patent case against BioNTech. However, court proceedings involving seven other patent rights will continue.

December 20, 2023

·

2 min read

·

Tyler Patchen

Business

CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

CureVac N.V. today announced dosing of the first participant in a Phase 2 study of the multivalent seasonal influenza vaccine candidate developed in collaboration with GSK.

May 28, 2024

·

6 min read

Business

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

CureVac N.V. (Nasdaq:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and The University of Texas MD Anderson Cancer Center today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.

April 16, 2024

·

8 min read